Suggestions
Julia Moore
Co-Founder and Managing Partner at Breakout Ventures
Julia Moore is a Managing Partner and co-founder of Breakout Ventures, focusing on investments in early-stage bioscience companies.23 She has over two decades of experience as an investor and operator of science-driven companies, helping founders navigate the translation of new life science technologies for customer adoption and scale.1
Moore's career highlights include:
- Managing Partner at Breakout Ventures (January 2021 - Present)3
- Partner at Breakout Ventures (2016 - December 2020)3
- Board Observer/Investor at NOETIK (2016 - 2020)2
- Portfolio Director at The Thiel Foundation (2015 - Present)3
- Kauffman Fellow (Class 17) from 2012 to 20143
She has also held positions at Stanford University, TriVascular, Inc., Kearny Venture Partners, and Thomas Weisel Partners.3 Moore holds a B.S. in Bioethics and Finance from the University of Virginia.3
As an investor, Moore serves on the boards of several companies, including Vitra Labs, Checkerspot, Inc., and Immusoft Corporation.3 She is known for her expertise in supporting science-driven companies and has been involved in various investment rounds and strategic decisions.3
Highlights
Excited to be speaking at the Women’s Venture Capital Summit next week, joining Jennifer Keiser Neundorfer and Elizabeth Yin to discuss Success Stories: Managers Who Emerged. Thank you to the wonderful women at Recast Capital (Courtney Russell McCrea, Sara Zulkosky) for hosting this discussion. Hope to see you there! #WVCS24
With Intelligence - Women's Summits Learn more: https://lnkd.in/gX87-aes
Incredibly proud to announce that Immusoft has dosed the first ever patient with an engineered b cell, and with none of the preconditioning or immunosuppression needed for gene modified stem cells or gene therapy. That's huge.
This engineered b cell has been modified to produce an enzyme the MPS 1 patient does not produce on their own, creating a sustained delivery of a protein therapeutic in the body. The patient is doing well after receiving the treatment in mid-November. It is thrilling to think about what it could mean for patients across so many diseases if armed with the ability to safely produce protein therapeutics in the body that could persist for many years. This is a momentous step toward making this vision of the future a reality.
Breakout Ventures California Institute for Regenerative Medicine (CIRM)
